Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Lung Infection

Drug Shortages Reported as New Program Created to Expedite Treatments for COVID-19

Diana Ernst, RPh

April 7, 2020

To expedite development, the FDA has created a special emergency program called the Coronavirus Treatment Acceleration Program.

Lung Infection

Point-of-Care COVID-19 Test Delivers Results Within Minutes

Diana Ernst, RPh

April 2, 2020

The Food and Drug Administration has issued an Emergency Use Authorization for the Abbott ID Now™ COVID-19 test.

Lung Infection

Non-Pharmaceutical Cloroquine Misuse for COVID-19 “Prevention” Leads to Severe Illness, Death

Diana Ernst, RPh

April 2, 2020

The product that sickened the couple was in powder form and was labeled “for Ornamental Fish Use Only.”

Lung Cancer

FDA Approves Imfinzi for Extensive-Stage Small Cell Lung Cancer

Diana Ernst, RPh

April 2, 2020

The approval was based on data from the CASPIAN study, an active-controlled, open-label trial that investigated the combination of durvalumab plus chemotherapy vs chemotherapy alone.

Asthma

ACAAI: Statement on Corticosteroid Use for Allergies, Asthma During COVID-19 Pandemic

Diana Ernst, RPh

April 1, 2020

The American College of Allergy, Asthma and Immunology (ACAAI) has issued a statement regarding the use of corticosteroids for patients with allergies and asthma.

CDC Declares Flu Epidemic After Death of 15 Children

Influenza

FDA to Review Baloxavir for Pediatric Use, Postexposure Prophylaxis of Influenza

Diana Ernst, RPh

April 1, 2020

Baloxavir inhibits the endonuclease activity of the polymerase acidic protein resulting in inhibition of influenza virus replication.

Lung Infection

FDA Allows Use of COVID-19 Convalescent Plasma for Severely Ill Patients Under Emergency IND

Diana Ernst, RPh

March 31, 2020

Convalescent plasma, which is collected from patients who have recovered from COVID-19, contains antibodies to SARS-CoV-2, the virus that causes the disease.

Frozen Fecal Capsules for C. difficile: An Alternative to Stool Transplants?

Lung Infection

FDA Issues Safety Alert About Fecal Microbiota Transplants and COVID-19

Diana Ernst, RPh

March 30, 2020

Treatment with fecal microbiota for transplantation (FMT) may potentially result in SARS-CoV-2 transmission, the virus that causes COVID-19, according to the FDA.

Lung Infection

Update on REMS-Required Testing During COVID-19 Pandemic

Diana Ernst, RPh

March 27, 2020

For patients suspected of having COVID-19, undergoing REMS-required testing to obtain a medication may put others at risk.

Lung Infection

FDA Issues Statement Regarding NSAID Use and COVID-19

Diana Ernst, RPh

March 25, 2020

The Food and Drug Administration has issued a statement regarding the use of nonsteroidal anti-inflammatory drugs in patients with coronavirus disease 2019.

Next post in Lung Infection